Company news

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A (SSE:688505) news

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A news releases on 6ix. Latest, Sep 5, 2026: "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.…

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A (SSE:688505) news

Press releases & updates

"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."Announcement on Shareholding Reduction Plan by Shareholder Holding More Than 5% of the Shares

"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."Semi-annual Report for 2026

"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

Announcement on the Resignation of Core Technical Personnel

Announcement on Resignation of Senior Management Members

Report for Q1 2026

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of FZ-P001 Sodium for Injection for Visualization of Malignant Lesions during Ovarian Cancer Surgery

Announcement on Requesting the General Meeting to Authorize the Board of Directors to Issue Shares to Specific Objects by Summary Procedure

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Change of Sponsor Representative for Continuous Supervision

Announcement on Earnings Preannouncement for 2025

Announcement on the Acceptance of the Drug Marketing Application for Aminolevulinic Acid Hydrochloride Powder for Oral Solution for Visualization in Glioma Surgery

Announcement on Result of Shareholding Reduction by Shareholder with Over 5% Shares

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Application Acceptance Notice for FZ-P001 Sodium Injection for Intraoperative Visualization of Malignant Lesions in Known or Suspected Lung Cancer Patients

Announcement on Cancellation of Board of Supervisors and Election of Employee Director for the 8th Board of Directors

Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares

Announcement on Changing Some Investment Projects Financed by Raised Funds

Announcement on Amending the Articles of Association and Its Annexes and Canceling the Board of Supervisors

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on the Voluntary Disclosure of Non-Approval of the Marketing Authorization Application for Obeticholic Acid Tablets for the Treatment of Primary Biliary Cholangitis

Announcement on Result of Shareholding Reduction by Shareholder

Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025

Announcement on Resolutions of the 10th Meeting of the 8th Board of Supervisors

Announcement on Convening the 2025 Semi-annual Performance Briefing

Indicative Announcement on Change of Equity to 5% for Shareholders with Over 5% Shares

Announcement on Implementation of Dividend Distribution for 2024

Announcement on Adjusting Member of Nomination Committee of the Board of Directors

Announcement on Resolution of the 2024 Annual General Meeting

Announcement on Share Reduction Plan for Shareholders with Over 5% Shares

Announcement on Voluntary Disclosure of Obtaining Notice on Acceptance of Drug Clinical Trial Application for FZ-P001 Sodium for Injection for Intraoperative Visualization of Malignant Lesions in Cancer

Announcement on Drug Price Adjustment

Notice on Convening the 2024 Annual General Meeting

Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing

Announcement on the Special Report on Deposit and Actual Use of Raised Funds in 2024

Announcement on Convening Annual Performance Briefing 2024

Announcement on Voluntary Disclosure Regarding the Completion of First Subject Enrollment in Confirmatory Clinical Trial for the Visualization of Bladder Cancer Surgery Using Aminolevulinic Acid Hydrochloride Granules

Announcement on Expiration of Plan of Shareholding Reduction by Shareholders with Over 5% Shares and Results of Shareholding Reduction

Preliminary Earnings Estimate for 2024

Announcement on 2024 Annual Earnings Preannouncement

Announcement on Obtaining Government Subsidies

Announcement on Voluntary Disclosure of the Acceptance of Drug Marketing Application for Obeticholic Acid Tablets for the Treatment of Primary Biliary Cholangitis

Report for Q3 2024

Announcement on Convening Performance Briefing for Q3 2024

Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase II Clinical Trial of Hemoporfin for Injection for the Treatment of Nevus Flammeus in the United States

Announcement on Participating in the 2024 Semi-annual Special Collective Performance Briefing for Pharmaceutical and Biological Products

Announcement on Voluntary Disclosure of the Completion of the First Subject Enrollment in Phase III Clinical Trial of FDA018 Antibody-drug Conjugate for the Treatment of Triple-negative Breast Cancer

Announcement on the Implementation of Semi-annual Dividend Distribution in 2024